Tweets
Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs https://t.co/BhxAMtjsZV
Dr. John Cush @RheumNow ( View Tweet )
1 hour 16 minutes ago
🚨NOW IN THE POSTER HALL: Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years
Check out the data in RA, PsA, AS, and nr-axSpA presented at EULAR 2026: https://t.co/QdAKpL3Vjv
Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/VYBvGp7Wnd
Dr. John Cush @RheumNow ( View Tweet )
2 hours 43 minutes ago
Patients with type 2 SLE present with fatigue, pain, brain fog and mood changes.
Type 1 & 2 often coexist but type 2 SLE impacts QOL.
@RheumNow #lupus #APLAR2026 https://t.co/aMtoIprPWG
sheila @RHEUMarampa ( View Tweet )
13 hours ago
Excites to report on #APLAR26 in Seoul, S. Korea for @RheumNow along with Drs. @RHEUMarampa and Peter Nash https://t.co/QImSxM7Izi
Jiha Lee @JihaRheum ( View Tweet )
13 hours 14 minutes ago
24-Week Interim Findings from a Randomized Phase 2 Study of Iptacopan (LNP023) Indicate High Remission Rates in Participants with Active ANCA-Associated Vasculitis https://t.co/cUNMo2ngeE and liver safety over time is?
Peter Nash @drpnash ( View Tweet )
13 hours 16 minutes ago
CDR209: A Novel TRBV9Ă—CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis https://t.co/RPD7FkgEdQ anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space
Peter Nash @drpnash ( View Tweet )
13 hours 16 minutes ago
Schett : in vivo the future if it works, during LD aciclovir, co-trimoxazole, CAR-T expansion amount not associated with toxicity, 3 month no vaccination window, all tissues B cell depletion , naive b cells return
APLAR Seoul 2026 #CART #RheumNow
Peter Nash @drpnash ( View Tweet )
13 hours 16 minutes ago
number of naive-like CAR-T infused associates with prolonged survival but highly variable
APLAR Seoul 2026 #CAR-T #Rheum Now
Peter Nash @drpnash ( View Tweet )
13 hours 16 minutes ago
Chan Hong Kong prediction CRS
80/20 - 80% CRS 20% hypoxia hypotension etc predictors 4 groups b cell load and IL6 level
APLAR Seoul 2026 #CART #RheumNow https://t.co/Q3C9RaYPFz
Peter Nash @drpnash ( View Tweet )
13 hours 17 minutes ago
Georg Schett : cure prime goal of therapy! remission off all treatment ,
APLAR Seoul 2026 #CART #RheumNow https://t.co/kygOGdxUSe
Peter Nash @drpnash ( View Tweet )
13 hours 17 minutes ago
lymphodepletion depends on individual cytokine profile and fludarabine PK effects efficacy
APLAR Seoul 2026 #CAR-T #Rheum Now
Peter Nash @drpnash ( View Tweet )
13 hours 18 minutes ago
Raff - Creative - lipid nanoparticle delivery
APLAR Seoul 2026 #CART #RheumNow https://t.co/1O11I5pR8P
Peter Nash @drpnash ( View Tweet )
13 hours 19 minutes ago
“Complex to manage” in SLE not for biologics
APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/4qeRGEVijs
Peter Nash @drpnash ( View Tweet )
13 hours 19 minutes ago
ExVivo advantages
APLAR Seoul 2026 #CART #RheumNow https://t.co/db2jIVDaik
Peter Nash @drpnash ( View Tweet )
13 hours ago
why biologics for “refractory”only - a life on steroids HCO MMF etc?
APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/Fa58nsF5Mk
Peter Nash @drpnash ( View Tweet )
13 hours ago
